Comparing two drugs for children with psoriatic arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with juvenile psoriatic arthritis for at least 3 months.
- You have active disease in at least 3 joints (swollen, painful, or limited movement).
- You have tried a disease-modifying antirheumatic drug (like methotrexate) for at least 2 months and it didn't work well or caused side effects.
- You cannot have other autoimmune or rheumatic diseases (like rheumatoid arthritis or other juvenile arthritis types).
- You must not have already tried and failed a biologic drug that targets TNF or IL-23 (like adalimumab or risankizumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
This study tests an investigational drug called Deucravacitinib to see if it can safely and effectively treat Juvenile Psoriatic Arthritis in children. You may be able to join if standard treatments haven't helped enough.
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
This trial compares two medicines for people with psoriatic arthritis who still have joint, skin, or nail symptoms after methotrexate. One medicine is apremilast (a pill), and the other is adalimumab (an injection). The study aims to see which works better.
This study tests different arthritis medications given in sequence for children and young adults with polyarticular JIA who did not get enough relief from a first TNF inhibitor. It aims to find which next treatment works best and is safe.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
Hear when a new Juvenile Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.